Current and novel cardiac support therapies

被引：4

作者：

Jugdutt B.I. ^{[1
]}

机构：

[1] Walter MacKenzie Health Sciences Center, Division of Cardiology, University of Alberta, Edmonton, AB T6G 2B7

来源：

Current Heart Failure Reports | 2009年 / 6卷 / 1期

基金：

加拿大健康研究院;

关键词：

Cardiac Resynchronization Therapy; Left Ventricular Assist Device; Mitral Valve Repair; Reverse Remodel; Optimal Medical Therapy;

D O I：

10.1007/s11897-009-0005-9

中图分类号：

学科分类号：

摘要：

Despite optimal medical therapy, many heart failure patients progress to end-stage disease associated with reduced quality of life and poor outcome. However, these patients can benefit from current novel cardiac support strategies, including ventricular assist devices (VADs), cardiac support devices (CSDs), and future cell- and/or matrix-based therapies. The most exciting goal in using VADs and CSDs is to achieve reverse remodeling, suppression of remodeling gene programs, and activation of myocardial recovery programs, which will improve left ventricular shape, size, and function. Long-term left VADs are effective, but recovery upon removal is uncommon. Passive CSDs (eg, Acorn devices) are very promising as long-term devices for therapy of end-stage heart failure and reversal of structural and biochemical remodeling. Expanding CSD use to include preventing progressive adverse left ventricular remodeling after ST-segment elevation myocardial infarction requires further study. The combination of cell- and/or matrix-based therapies with CSDs is under investigation. © Current Medicine Group, LLC 2009.

引用

页码：19 / 27

页数：8

共 59 条

[1]

Hunt S.A., ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure), J Am Coll Cardiol, 46, (2005)

[2]

Mann D.L., Pathophysiology of heart failure, Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, pp. 541-560, (2008)

[3]

Lowes B.D., Gilbert E.M., Abraham W.T., Et al., Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents, N Engl J Med, 346, pp. 1357-1365, (2002)

[4]

Jugdutt B.I., Ventricular remodeling postinfarction and the extracellular collagen matrix: When is enough enough?, Circulation, 108, pp. 1395-1403, (2003)

[5]

Jugdutt B.I., Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways, Curr Drug Targets, Cardiovasc Haematol Disord, 3, pp. 1-30, (2003)

[6]

McCarthy P.M., Surgical management of heart failure, Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, pp. 665-684, (2008)

[7]

Taylor D.O., Edwards L.B., Boucek M.M., Et al., Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult heart transplant report-2007, J Heart Lung Transplant, 26, pp. 769-781, (2007)

[8]

Goldstein D.J., Smego D., Michler R.E., Surgical aspects of congestive heart failure, Heart Fail Rev, 11, pp. 171-192, (2006)

[9]

Wellnhofer E., Olariu A., Klein C., Magnetic resonance lowdose dobutamine test is superior to SCAR quantification for the prediction of functional recovery, Circulation, 109, pp. 2172-2174, (2004)

[10]

Aziz T., Burgess M., Rahman A.N., Et al., Cardiac transplantation for cardiomyopathy and ischemic heart disease: Differences in outcome up to 10 years, J Heart Lung Transplant, 20, pp. 525-533, (2001)

← 1 2 3 4 5 6 →